Printer Friendly

Birt-Hogg-Dube Syndrome Caused by a Novel Mutation in the FLCL Gene.

1. Background

Birt-Hogg-Dube syndrome is marked by kidney tumors, cystic lung disease, and skin fibrofolliculomas. It has also been implicated in the formation of tumors in other organs, particularly thyroid and colon though these have had inconsistent reports in the literature [1, 2]. There are isolated case reports of other multiple tumors forming in patients with Birt-Hogg-Dube syndrome, though these have not thus far shown a clear association with the mutation of the folliculin (FLCN) gene responsible for the syndrome. It traditionally presents in a familial, autosomal dominant pattern with high penetrance, but there are few reports in the literature of unique mutations presenting with this syndrome [3, 4].

Patients with this condition are at greatly increased risk of kidney cancer and pneumothorax compared to the general population. Kidney tumors can range from benign to malignant, though their malignancies tend to be of lower grade. However, their risk of kidney cancer is roughly seven times that of the general population. Pneumothorax is a complication in roughly 30% of people with Birt-Hogg-Dube syndrome and is secondary to lung cysts. However, lung dysfunction is usually minimal with most people showing normal pulmonary function testing or minimal airway obstruction [5]. The skin findings are typically fibrofolliculomas, usually on the face, and are the most common finding in Birt-Hogg-Dube syndrome. These skin lesions maybe mildly disfiguring but are usually benign.

This genetic, autosomal dominant condition is caused by a mutation of the FLCN gene on chromosome 17. Its exact function is unknown, but it is thought to be a tumor suppressor gene. Historically, this was thought to be a primarily familial disease, but reports like the one below identify isolated cases identifying a novel FLCN mutation.

2. Case Report

A 34-year-old female was seen in the emergency department for abdominal pain. Her workup included a CT abdomen where she was found to have bilateral renal masses: 2.4 cm on the right and 7.6 cm on the left (Figure 1). Also noted were multiple small cysts in the lung bases. The rest of the workup was unremarkable and her abdominal pain resolved with conservative management alone. She was referred to urology where it was recommended that her left kidney tumor be resected and to defer the right pending pathology results. Notably, she had no prior medical history and no relevant surgical history and had otherwise been healthy and well. She has two siblings without lung, skin, or kidney symptoms and her parents are likewise healthy. She has a 15-year-old son who is healthy. There were no consistent skin findings on exam.

Pulmonary evaluation with a CT of chest identified basilar predominant multiple lung cysts with the largest cysts measuring approximately 1.6cm. Several <6mm partially solid nodules were noted as well. Spirometry, diffusion capacity, and plethysmography were all within normal limits. She did complain of mild dyspnea, but that this was intermittent and had a significant anxiety component.

She eventually underwent resection of the left kidney mass with a partial nephrectomy and a final pathologic diagnosis of an oncocytoma, which is a typical tumor type for Birt-Hogg-Dube syndrome. Her postoperative course was unremarkable with a planned sequential right nephrectomy pending further evaluation.

Birt-Hogg-Dube syndrome was suspected given this patient's basilar predominant multiple lung cysts and bilateral renal masses, but without skin findings the diagnosis was in question. There are no universally accepted diagnostic criteria, but typically either skin findings or a pathologic mutation must accompany the lung and kidney pathology to solidify the diagnosis. Genetic testing was thus obtained via a blood sample. The FLCN gene of the patient was sequenced with any deletions or duplications included. It showed a heterozygous mutation of the FLCN gene (c.780-2A>G) predicted to disrupt the canonical splicing acceptor site of exon 8 of FLCN. This mutation has not been previously described in the human genetic mutation database (HGMD). On further review, the HGMD has over 160 individual mutations identified in the FLCN gene. However, the majority of identified familiar mutations in the FLCN gene are confined to two separate mutations (c.1285dupC and c.1285delC).

The consistent FLCN gene mutation along with renal and lung findings supported the diagnosis of Birt-Hogg-Dube syndrome. The patient was referred to a medical geneticist. It was noted that the patient was the child of second cousins but otherwise she had no family with syndromic complaints consistent with Birt-Hogg-Dube syndrome. However, clinical manifestations of this disease process can be subtle and given that her kidney and lung manifestations were found incidentally, these could have remained unidentified in her family members. Genetic testing of her family is pending.

On follow-up imaging, her lung cysts have remained stable, but her right kidney tumor has increased to 2.8cm (previously 2.4cm) and a new, small 8mm satellite lesion was identified. Based on these findings resection was recommended for her given the high rate for malignant transformation.

3. Discussion

This case presents a novel FLCN mutation causing the lung and kidney manifestations of Birt-Hogg-Dube syndrome but none of the more typical skin findings. Given no consistent complaints from her family history, this may be a spontaneous mutation in the proband. However, given the purely visceral organ effects of this particular mutation, other family members may have been affected subclinically. The number of individual FLCN mutations (>160) in the HGMD also suggests that novel mutation in the FLCL gene may be a more common cause of Birt-Hogg-Dube syndrome than has previously been described.

This case is particularly notable for her mutation causing only lung and kidney findings while sparing the integument. It is possible that the plethora of novel mutations of FLCN belies a much more variable clinical presentation than previously thought.

We recommend genetic testing in all cases of suspected Birt-Hogg-Dube syndrome even without family history as spontaneous mutations may be a common cause of this disorder. With more widespread availability of genetic analysis in patients and their family members, the true rate of spontaneous mutation will hopefully be elucidated and future studies on Birt-Hogg-Dube syndrome are warranted to identify the true novel mutation rate as well as genetic factors that could predict organ systems affected.

https://doi.org/10.1155/2018/4173704

Disclosure

The authors (Charles Volk, Gregory Matwiyoff) are United States military service members. This work was prepared as part of their official duties. Title 17 USC [section]105 provides that "copyright protection under this title is not available for any work of the United States Government." Title 17 USC [section]101 defines a US Government work as a work prepared by a military service member or employee of the US Government as part of that person's official duties. The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Department of the Navy, the Department of Defense, or the US Government. None of the authors have any relevant financial disclosures.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

Special thanks are due to Mary Willis, M.D., Medical Genetics, Naval Medical Center, San Diego, and Yuan Xue, M.D., Ph.D., and FACMG, Clinical Molecular Genetics, Fulgent Diagnostics.

References

[1] M. S. Nahorski, D. H. K. Lim, L. Martin et al., "Investigation of the Birt-Hogg-Dube tumour suppressor gene (FLCN) in familial and sporadic colorectal cancer," Journal of Medical Genetics, vol. 47, no. 6, pp. 385-390, 2010.

[2] B. Zbar, "Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dube syndrome," Cancer Epidemiology, Biomarkers & Prevention, vol. 11, no. 4, pp. 393-400, 2002.

[3] J. G. Rivas, D. M. Carrion, S. A. Y. Gregorio, M. Alvarez-Maestro, A. T. Gomez, and J. C. Ledo, "A novel heterozygous mutation in the Birt-Hogg-Dube syndrome," Archivos Espanoles de Urologia, vol. 70, no. 7, pp. 675-678, 2017.

[4] G. Kayhan, N. Yilmaz Demirci, H. Turktas, and M. A. Ergun, "Birt-Hogg-Dube Syndrome with a Novel Mutation in the FLCN Gene," Genetic Testing and Molecular Biomarkers, vol. 21, no. 10, pp. 632-634, 2017.

[5] L. S. Schmidt and W. M. Linehan, "Molecular genetics and clinical features of Birt-Hogg-Dube syndrome," Nature Reviews Urology, vol. 12, no. 10, pp. 558-569, 2015.

Charles Volk and Gregory Matwiyoff

Medical Corps, United States Navy, Pulmonary Department, Naval Medical Center, San Diego, 34800 Bob Wilson Drive, San Diego, CA 92134, USA

Correspondence should be addressed to Charles Volk; charles.g.volk.mil@mail.mil

Received 1 August 2018; Accepted 24 October 2018; Published 7 November 2018

Academic Editor: Philip D. Cotter

Caption: Figure 1: Image showing lung cysts (a), right kidney mass of 2.4 cm (b), and left kidney mass of 7.6 cm (c), which was later identified as an oncocytoma.
COPYRIGHT 2018 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Case Report
Author:Volk, Charles; Matwiyoff, Gregory
Publication:Case Reports in Genetics
Date:Jan 1, 2018
Words:1448
Previous Article:LAMA2 Congenital Muscle Dystrophy: A Novel Pathogenic Mutation in Bulgarian Patient.
Next Article:A Rare Case of Severe Congenital RYRl-Associated Myopathy.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters